Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 13,736 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: HIV Infections
Interventions: Hepatitis A Vaccine (Inactivated); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more

Conditions: Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions: cisplatin, ifosfamide, paclitaxel, vinblastine; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 78
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 57 more

Conditions: Substance Use Disorders, Insomnia
Interventions: Brief Behavioral Therapy for Insomnia (BBTI); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Interventions: Placebo, Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions: BCG TICE Vaccine; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Retinal Vein Occlusion
Interventions: Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), Pro re nata (prn) ranibizumab, Pro re nata (prn) Laser photocoagulation; Drug · Procedure
Lead sponsor: Peter A Campochiaro, MD; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urinary Incontinence (UI)
Interventions: Tolterodine, Behavioral training; Drug · Behavioral
Lead sponsor: Carelon Research; Other
Eligibility: 21 Years and older · Female only
Enrollment: 307 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 9
States / cities: Birmingham, Alabama • San Diego, California • Maywood, Illinois + 6 more

Conditions: Sarcoma
Interventions: filgrastim, dacarbazine, doxorubicin hydrochloride, ifosfamide, semaxanib, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 207
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 163 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: National Parkinson Foundation; Other
Eligibility: Not listed
Enrollment: 13,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 18
States / cities: Phoenix, Arizona • Sunnyvale, California • Washington D.C., District of Columbia + 14 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: Placebo, Cenicriviroc; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 204
States / cities: Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
Interventions: AMX0035, Placebo; Drug · Other
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 21 more

Conditions: HIV Infections
Interventions: CPI-1189; Drug
Lead sponsor: Centaur Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: San Diego, California • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Hand Injuries
Interventions: MoTrack Therapy; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions: Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 15
States / cities: Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 85
States / cities: Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 30 more

Conditions: Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 493
States / cities: Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more

Conditions: Myelodysplastic Syndromes
Interventions: TEW-7197; Drug
Lead sponsor: MedPacto, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Tampa, Florida • Baltimore, Maryland • The Bronx, New York

Conditions: Peripheral Pulmonary Nodules
Interventions: Navigation guided bronchoscopy; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Years to 49 Years
Enrollment: 345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 11
States / cities: Miami, Florida • Chicago, Illinois • Bardstown, Kentucky + 8 more

Conditions: Suspected Primary Prostate Cancer
Interventions: ProxiScan (scintigraphic rectal probe); Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Endocrine Tumors
Interventions: lanreotide (Autogel formulation), Placebo; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 8
States / cities: Los Angeles, California • Iowa City, Iowa • Baltimore, Maryland + 5 more

Search by objective public record fields.

A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

Feasibility of Brief Behavioral Therapy for Insomnia (BBTI) in SUD Recovery

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

Behavior Enhances Drug Reduction of Incontinence (BE-DRI)

Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma

Long-Term Results in Mechanically Ventilated Individuals With Acute Lung Injury/Acute Respiratory Distress Syndrome

Parkinson's Foundation Quality Improvement Initiative

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

Use of MoTrack Therapy in At-Home Hand Rehabilitation

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS

Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours